Case number 2020-2134
Cephalon, Inc. v. Slayback Pharma LLC > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Oct 4, 2021 | 0 | CEPHALON, INC. v. SLAYBACK PHARMA LLC [RULE 36 JUDGMENT] [nonprecedential] (0) |
| Sep 14, 2021 | 72 | 18 paper copies of Doc. No. [71] received from Appellants Apotex Corp., Apotex Inc. and Mylan Laboratories Limited. [800007] [VDW] [Entered: 09/16/2021 02:07 PM] (0) |
| Sep 13, 2021 | 71 | Petition for en banc rehearing filed by Appellants Apotex Inc., Apotex Corp. and Mylan Laboratories Limited. Service: 09/13/2021 by email. [798916] [20-2134] [Steven Feldman] [Entered: 09/13/2021 06:43 PM] (30) |
| Aug 13, 2021 | 70 | JUDGMENT. AFFIRMED. Issued pursuant to Federal Circuit Rule 36. Terminated on the merits after oral argument. COSTS: Costs taxed against Appellant(s). Mandate to issue in due course. For information regarding costs, petitions for rehearing, and petitions for writs of certiorari click here. Service as of this date by the Clerk of Court. [792414] [20-2134, 20-2137] [MJL] [Entered: 08/13/2021 09:19 AM] (2) |
| Aug 3, 2021 | 69 | Submitted after ORAL ARGUMENT to Panel: Newman, Circuit Judge; Clevenger, Circuit Judge and Taranto, Circuit Judge.Arguing counsel: Mr. Steven Eric Feldman for Apotex Inc. and Apotex Corp., Nicole W. Stafford for Mylan Laboratories Limited and David I. Berl for Cephalon, Inc., Teva Pharmaceuticals International GmbH, and Eagle PHamaceuticals, Inc.Oral Argument Audio available here. [790479] [JCP] [Entered: 08/04/2021 08:23 AM] (0) |
| Aug 2, 2021 | 68 | ORDER granting motion [66] to dismiss Fresenius Kabi USA, LLC in appeal no. 20-2134 and to dismiss appeal no. 20-2316 pursuant to FRAP 42(b). The revised official caption is reflected in the order; issuing mandate in 20-2136. By: Merits Panel (Per Curiam). Service as of this date by the Clerk of Court. [789971] [20-2134, 20-2136] [MVH] [Entered: 08/02/2021 03:01 PM] (3) |
| Jul 30, 2021 | 67 | Response to notice of oral argument from Appellant Mylan Laboratories Limited. Service: 07/30/2021 by email. [789750] [20-2134] [Nicole Stafford] [Entered: 07/30/2021 09:26 PM] (1) |
| Jul 30, 2021 | 66 | MOTION of Appellees Cephalon, Inc., Teva Pharmaceuticals International GmbH, Eagle Pharmaceuticals, Inc. and Appellant Fresenius Kabi USA, LLC to voluntarily dismiss appeal pursuant to FRAP 42(b). Service: 07/30/2021 by email. [789745] [20-2134] [David Berl] [Entered: 07/30/2021 07:07 PM] (13) |
| Jul 30, 2021 | 65 | Corrected Response to notice of oral argument from Appellants Apotex Corp. and Apotex Inc.. Service: 07/30/2021 by email. [789711] [20-2134] [Steven Feldman] [Entered: 07/30/2021 04:45 PM] (1) |
| Jul 28, 2021 | 64 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: ERROR: Appellants' responses to the notice of oral argument [61] and [62] divide rebuttal time into half minutes. CORRECTION: Argument time may not be divided into half minutes. Corrected responses in whole minutes should be filed no later than 07/30/2021. [789180] [MJL] [Entered: 07/28/2021 02:31 PM] (0) |
| Jul 15, 2021 | 63 | Response to notice of oral argument from Appellees Teva Pharmaceuticals International GmbH, Cephalon, Inc. and Eagle Pharmaceuticals, Inc.. Service: 07/15/2021 by email. [786612] [20-2134] [David Berl] [Entered: 07/15/2021 04:29 PM] (1) |
| Jul 15, 2021 | 62 | Response to notice of oral argument from Appellants Apotex Corp. and Apotex Inc.. Service: 07/15/2021 by email. [786579] [20-2134] [Steven Feldman] [Entered: 07/15/2021 03:53 PM] (1) |
| Jul 15, 2021 | 61 | Response to notice of oral argument from Appellant Fresenius Kabi USA, LLC. Service: 07/15/2021 by email. [786543] [20-2134] [Imron Aly] [Entered: 07/15/2021 02:57 PM] (1) |
| Jun 21, 2021 | 60 | NOTICE OF TELEPHONIC ORAL ARGUMENT. Panel: 2108B. Case scheduled August 3, 2021. Response to Notice of Oral Argument due: 07/15/2021. Please review the attached Notice. The response to notice of oral argument form can be found here. The Oral Argument Guide can be found here. The Counsel Telephonic Argument Orientation Information can be found here. Service as of this date by the Clerk of Court. [781488] [MVH] [Entered: 06/21/2021 04:34 PM] (1) |
| May 11, 2021 | 58 | The following conflict dates submitted by David I. Berl for Cephalon, Inc., Teva Pharmaceuticals International GmbH, and Eagle Pharmaceuticals, Inc. have been accepted by the court: 07/06/2021, 07/07/2021, 07/08/2021, 07/09/2021, 11/01/2021, 11/02/2021, 11/03/2021, 11/04/2021, 11/05/2021. [774161] [MJL] [Entered: 05/11/2021 08:18 AM] (0) |
| May 11, 2021 | 57 | The following conflict date submitted by Nicole W. Stafford for Mylan Laboratories Limited has been accepted by the court: 07/06/2021. [774160] [MJL] [Entered: 05/11/2021 08:16 AM] (0) |
| May 10, 2021 | 56 | Notice from Appellees Teva Pharmaceuticals International GmbH, Cephalon, Inc. and Eagle Pharmaceuticals, Inc. regarding conflicts with oral argument. Service: 05/10/2021 by email. [774149] [20-2134] [David Berl] [Entered: 05/10/2021 07:18 PM] (4) |
| May 5, 2021 | 54 | Notice from Appellants Apotex Corp. and Apotex Inc. regarding conflicts with oral argument. None. Service: 05/05/2021 by email. [773176] [20-2134] [Steven Feldman] [Entered: 05/05/2021 03:44 PM] (0) |
| May 5, 2021 | 53 | Notice from Appellees Teva Pharmaceuticals International GmbH, Cephalon, Inc. and Eagle Pharmaceuticals, Inc. regarding conflicts with oral argument. Service: 05/05/2021 by email. [773166] [20-2134] [David Berl] [Entered: 05/05/2021 03:25 PM] (3) |
| May 5, 2021 | 52 | Notice from Appellant Fresenius Kabi USA, LLC regarding conflicts with oral argument. None. Service: 05/05/2021 by email. [773157] [20-2134] [Imron Aly] [Entered: 05/05/2021 03:07 PM] (0) |
| May 5, 2021 | 51 | Notice from Appellant Mylan Laboratories Limited regarding conflicts with oral argument. Service: 05/05/2021 by email. [773154] [20-2134] [Nicole Stafford] [Entered: 05/05/2021 03:04 PM] (3) |
| May 4, 2021 | 55 | 6 paper copies of Doc. No. [44], [43] received from Appellants Apotex Corp. and Apotex Inc.. [773557] [VDW] [Entered: 05/07/2021 08:13 AM] (0) |
| May 4, 2021 | 50 | Amended Entry of appearance for Daniel G. Brown as counsel for Appellee Eagle Pharmaceuticals, Inc.. Service: 05/04/2021 by email. [772946] [20-2134] [Daniel Brown] [Entered: 05/04/2021 05:22 PM] (2) |
| Apr 30, 2021 | 59 | 6 paper copies of Doc. No. [41] received from Appellees Cephalon, Inc., Eagle Pharmaceuticals, Inc. and Teva Pharmaceuticals International GmbH. [777410] [VDW] [Entered: 05/27/2021 01:50 PM] (0) |
| Apr 29, 2021 | 49 | 6 paper copies of Doc. No. [35], [34], [46] received from Appellants Fresenius Kabi USA, LLC and Mylan Laboratories Limited. [772737] [VDW] [Entered: 05/04/2021 11:30 AM] (0) |
| Apr 28, 2021 | 48 | Notice to counsel: The Clerk's Office directs that outstanding paper copies of all briefs and appendices in this case must be submitted on or before May 5, 2021. See Administrative Order No. 20-01 (Mar. 20, 2020). [771771] [KMH] [Entered: 04/28/2021 02:19 PM] (0) |
| Apr 28, 2021 | 47 | Notice to Advise of Scheduling Conflicts. Arguing counsel must advise of, and show good cause for, any scheduling conflicts during the upcoming court session months listed in the attached notice. The Response to Notice to Advise of Scheduling Conflicts can be found here. The Oral Argument Guide can be found here. [771765] [KMH] [Entered: 04/28/2021 02:10 PM] (1) |
| Apr 27, 2021 | 46 | MODIFIED ENTRY: CORRECTED OPENING BRIEF FILED by Appellants Fresenius Kabi USA, LLC and Mylan Laboratories Limited. Service: 04/27/2021 by email. [771566]--[Edited 04/28/2021 by KMH - compliance review complete] [Imron Aly] [Entered: 04/27/2021 04:46 PM] (225) |
| Apr 27, 2021 | 45 | Notice of Correction to Doc No. [22] for Appellants Fresenius Kabi USA, LLC and Mylan Laboratories Limited. Service: 04/27/2021 by email. [771564] [20-2134] [Imron Aly] [Entered: 04/27/2021 04:43 PM] (4) |
| Apr 27, 2021 | 44 | MODIFIED ENTRY: CORRECTED REPLY BRIEF FILED by Appellants Apotex Corp. and Apotex Inc.. Service: 04/27/2021 by email. [771522] --[Edited 04/28/2021 by KMH - compliance review complete] [Steven Feldman] [Entered: 04/27/2021 03:32 PM] (46) |
| Apr 27, 2021 | 43 | MODIFIED ENTRY: CORRECTED OPENING BRIEF FILED by Appellants Apotex Corp. and Apotex Inc.. Service: 04/27/2021 by email. [771520]--[Edited 04/28/2021 by KMH - compliance review complete] [Steven Feldman] [Entered: 04/27/2021 03:31 PM] (216) |
| Apr 27, 2021 | 42 | Notice of Correction to Doc No. [17], [29] for Appellants Apotex Corp. and Apotex Inc.. Service: 04/27/2021 by email. [771519] [20-2134] [Steven Feldman] [Entered: 04/27/2021 03:30 PM] (5) |
| Apr 26, 2021 | 37 | Certificate of Compliance with Fed. Cir. R. 25.1(c)(2) for Appellants Apotex Corp., Apotex Inc., Fresenius Kabi USA, LLC and Mylan Laboratories Limited. Service: 04/26/2021 by email. [771286] [20-2134] [Imron Aly] [Entered: 04/26/2021 05:50 PM] (3) |
| Apr 26, 2021 | 35 | MODIFIED ENTRY: CONFIDENTIAL APPENDIX FILED by Appellants Fresenius Kabi USA, LLC and Mylan Laboratories Limited. Service: 04/26/2021 by email. [771281]--[Edited 04/28/2021 by KMH - compliance review complete] [Imron Aly] [Entered: 04/26/2021 05:40 PM] (0) |
| Apr 26, 2021 | 36 | MODIFIED ENTRY: APPENDIX FILED by Appellants Fresenius Kabi USA, LLC and Mylan Laboratories Limited. Service: 04/26/2021 by email. [771284] --[Edited 04/28/2021 by KMH - compliance review complete] [Imron Aly] [Entered: 04/26/2021 05:48 PM] (1799) |
| Apr 26, 2021 | 38 | Joint Statement of Compliance with Fed. Cir. R. 33 for Appellants Apotex Corp., Apotex Inc., Fresenius Kabi USA, LLC, Mylan Laboratories Limited and Appellees Cephalon, Inc., Eagle Pharmaceuticals, Inc. and Teva Pharmaceuticals International GmbH. Service: 04/26/2021 by email. [771287] [20-2134] [Imron Aly] [Entered: 04/26/2021 05:50 PM] (4) |
| Apr 26, 2021 | 39 | Certificate of Compliance with Fed. Cir. R. 25.1(c)(2) for Appellees Cephalon, Inc., Eagle Pharmaceuticals, Inc. and Teva Pharmaceuticals International GmbH. Service: 04/26/2021 by email. [771292] [20-2134] [Ben Picozzi] [Entered: 04/26/2021 06:22 PM] (3) |
| Apr 26, 2021 | 40 | Notice of Correction to Doc No. [25] for Appellees Cephalon, Inc., Eagle Pharmaceuticals, Inc. and Teva Pharmaceuticals International GmbH. Service: 04/26/2021 by email. [771294] [20-2134] [David Berl] [Entered: 04/26/2021 06:36 PM] (4) |
| Apr 26, 2021 | 41 | MODIFIED ENTRY: CORRECTED RESPONSE BRIEF FILED by Appellees Cephalon, Inc., Eagle Pharmaceuticals, Inc. and Teva Pharmaceuticals International GmbH. Service: 04/26/2021 by email. [771295]--[Edited 04/28/2021 by KMH - compliance review complete] [David Berl] [Entered: 04/26/2021 06:39 PM] (139) |
| Apr 21, 2021 | 34 | MODIFIED ENTRY: CORRECTED REPLY BRIEF FILED by Appellants Fresenius Kabi USA, LLC and Mylan Laboratories Limited. Service: 04/21/2021 by email. [770261] --[Edited 04/23/2021 by KMH - compliance review complete] [Imron Aly] [Entered: 04/21/2021 02:05 PM] (42) |
| Apr 20, 2021 | 33 | NOTICE OF NON-COMPLIANCE: The submission of Appellants Apotex Corp., Apotex Inc., Fresenius Kabi USA, LLC and Mylan Laboratories Limited, Reply Briefs [29], [30], are not in compliance with the rules of this court (see attached). Compliant documents due on 04/27/2021. Unless ordered otherwise, the deadline for any responsive filing runs from service of the original version. Service as of this date by the Clerk of Court. [769940] [KMH] [Entered: 04/20/2021 01:16 PM] (1) |
| Apr 13, 2021 | 32 | **TEXT ONLY** ORDER granting motion to extend time to file appendix [31] filed by Appellants Apotex Inc., Apotex Corp., Mylan Laboratories Limited, Fresenius Kabi USA, LLC and Appellees Cephalon, Inc., Teva Pharmaceuticals International GmbH and Eagle Pharmaceuticals, Inc. The appendix is due 04/26/2021. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [768182] [KMH] [Entered: 04/13/2021 09:07 AM] (0) |
| Apr 9, 2021 | 31 | MOTION of Appellants Apotex Corp., Apotex Inc., Fresenius Kabi USA, LLC, Mylan Laboratories Limited and Appellees Cephalon, Inc., Eagle Pharmaceuticals, Inc. and Teva Pharmaceuticals International GmbH to extend the time to 04/26/2021 to file the appendix. Service: 04/09/2021 by email. [767831] [20-2134] [Ben Picozzi] [Entered: 04/09/2021 05:42 PM] (37) |
| Apr 5, 2021 | 30 | REPLY BRIEF FILED by Appellants Apotex Corp., Apotex Inc., Fresenius Kabi USA, LLC and Mylan Laboratories Limited. Service: 04/05/2021 by email. [766777] [20-2134] This document is non-compliant. See Doc No. [33] [Imron Aly] [Entered: 04/05/2021 07:13 PM] (41) |
| Apr 5, 2021 | 29 | REPLY BRIEF FILED by Appellants Apotex Inc., Apotex Corp., Fresenius Kabi USA, LLC and Mylan Laboratories Limited. Service: 04/05/2021 by email. [766722] [20-2134] This document is non-compliant. See Doc No. [33] [Steven Feldman] [Entered: 04/05/2021 03:33 PM] (44) |
| Feb 25, 2021 | 28 | **TEXT ONLY** ORDER granting motion to extend time to file brief [26] filed by Appellants Apotex Inc., Apotex Corp., Mylan Laboratories Limited and Fresenius Kabi USA, LLC. The reply brief is due 04/05/2021. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [758586] [KMH] [Entered: 02/25/2021 11:05 AM] (0) |
| Feb 25, 2021 | 27 | This entry was made in error and has been removed from the docket. NOTICE OF NON-COMPLIANCE: The submission of Appellees Cephalon, Inc., Eagle Pharmaceuticals, Inc. and Teva Pharmaceuticals International GmbH, Response Brief [25], is not in compliance with the rules of this court (see attached). Compliant document due on 03/04/2021. Unless ordered otherwise, the deadline for any responsive filing runs from service of the original version. Service as of this date by the Clerk of Court. [758581] [KMH] [Entered: 02/25/2021 10:56 AM] (0) |
| Feb 24, 2021 | 26 | MOTION of Appellants Fresenius Kabi USA, LLC, Mylan Laboratories Limited, Apotex Inc. and Apotex Corp. to extend the time to 04/05/2021 to file brief. Service: 02/24/2021 by email. [758481] [20-2134] [Imron Aly] [Entered: 02/24/2021 10:54 PM] (24) |
| Feb 12, 2021 | 25 | MODIFIED ENTRY: RESPONSE BRIEF FILED by Appellees Cephalon, Inc., Eagle Pharmaceuticals, Inc. and Teva Pharmaceuticals International GmbH. Service: 02/12/2021 by email. Unless ordered otherwise, any responsive deadline runs from the date of service of this brief. See Fed. Cir. R. 31. [756001] --[Edited 03/01/2021 by KMH - Reason: compliance review complete] This document has been corrected. See Doc No. [41] [David Berl] [Entered: 02/12/2021 07:40 PM] (139) |
| Dec 17, 2020 | 24 | ORDER granting motion [23]. Service as of this date by the Clerk of Court. [743501] [NL] [Entered: 12/17/2020 01:51 PM] (2) |
| Nov 13, 2020 | 23 | MOTION of Appellees Cephalon, Inc., Teva Pharmaceuticals International GmbH and Eagle Pharmaceuticals, Inc. to waive the requirements regarding the brief (waive the requirements of Federal Circuit Rule 32 and permit a 21,000-word responsive brief). Service: 11/13/2020 by email. [735500] [20-2134]--[Edited 11/13/2020 by MMA to add party filer] [Ben Picozzi] [Entered: 11/13/2020 04:03 PM] (13) |
| Nov 10, 2020 | 22 | MODIFIED ENTRY: CORRECTED BRIEF FILED by Appellants Fresenius Kabi USA, LLC and Mylan Laboratories Limited. Service: 11/10/2020 by email. [734867] --[Edited 11/12/2020 by KMH - compliance review complete] [Imron Aly] [Entered: 11/10/2020 04:56 PM] (225) |
| Nov 10, 2020 | 21 | NOTICE OF NON-COMPLIANCE: The submission of Appellants Fresenius Kabi USA, LLC and Mylan Laboratories Limited, Opening Brief [18], is not in compliance with the rules of this court (see attached). Compliant document due on 11/18/2020. Unless ordered otherwise, the deadline for any responsive filing runs from service of the original version. Service as of this date by the Clerk of Court. [734754] [KMH] [Entered: 11/10/2020 01:34 PM] (1) |
| Nov 9, 2020 | 20 | **TEXT ONLY** ORDER granting motion to extend time to file brief [19] filed by Appellees Cephalon, Inc., Teva Pharmaceuticals International GmbH and Eagle Pharmaceuticals, Inc. The response brief is due 02/12/2021. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [734399] [KMH] [Entered: 11/09/2020 09:15 AM] (0) |
| Nov 5, 2020 | 19 | MOTION of Appellees Cephalon, Inc., Teva Pharmaceuticals International GmbH and Eagle Pharmaceuticals, Inc. to extend the time to 02/12/2021 to file brief. Service: 11/05/2020 by email. [734015] [20-2134] [Ben Picozzi] [Entered: 11/05/2020 03:43 PM] (18) |
| Nov 4, 2020 | 18 | OPENING BRIEF FILED by Appellants Mylan Laboratories Limited and Fresenius Kabi USA, LLC. Service: 11/04/2020 by email. [733731] [20-2134] This document is non-compliant. See Doc No. [21] [Imron Aly] [Entered: 11/04/2020 06:19 PM] (225) |
| Nov 4, 2020 | 17 | MODIFIED ENTRY: BRIEF FILED by Appellants Apotex Corp. and Apotex Inc.. Service: 11/04/2020 by email. Unless ordered otherwise, any responsive deadline runs from the date of service of this brief. See Fed. Cir. R. 31. [733702] --[Edited 11/10/2020 by KMH - compliance review complete] This document has been corrected. See Doc No. [43] [Steven Feldman] [Entered: 11/04/2020 04:58 PM] (216) |
| Sep 16, 2020 | 16 | **TEXT ONLY** ORDER granting motion to extend time to file brief [15] filed by Appellants Apotex Inc., Apotex Corp., Mylan Laboratories Limited and Fresenius Kabi USA, LLC. The opening briefs are due 11/04/2020. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [722040] [KMH] [Entered: 09/16/2020 09:38 AM] (0) |
| Sep 14, 2020 | 15 | MOTION of Appellants Apotex Corp., Apotex Inc., Fresenius Kabi USA, LLC and Mylan Laboratories Limited to extend the time to 11/04/2020 to file brief. [Consent: unopposed]. Service: 09/14/2020 by email. [721373] [20-2134] [Imron Aly] [Entered: 09/14/2020 03:09 PM] (23) |
| Aug 25, 2020 | 14 | Corrected Entry of appearance for Steven Eric Feldman; Sherry L. Rollo; Daniel R. Cherry; John D. Cravero as counsel for Appellants Apotex Corp. and Apotex Inc.. Service: 08/25/2020 by clerk. [717444] [20-2134] [Sherry Rollo] [Entered: 08/25/2020 03:11 PM] (2) |
| Aug 24, 2020 | 13 | Note to File: The following cases are consolidated: 20-2134 Lead with 20-2136 and 20-2137 Consolidated Member Cases. The parties must file all documents in the lead appeal only. [716966] [20-2134, 20-2136, 20-2137] [KMH] [Entered: 08/24/2020 01:37 PM] (0) |
| Aug 24, 2020 | 12 | ORDER consolidating appeals 20-2134, 20-2136, and 20-2137. Appellants' opening briefs are due no later than October 5, 2020. Service as of this date by the Clerk of Court. [716929] [20-2134, 20-2136, 20-2137] [KMH] [Entered: 08/24/2020 12:44 PM] (2) |
| Aug 21, 2020 | 11 | NOTICE OF NON-COMPLIANCE: The submission of Appellants Apotex Corp. and Apotex Inc., Entry of Appearance [8], is not in compliance with the rules of this court (see attached). Compliant document due on 08/28/2020. Service as of this date by the Clerk of Court. [716437] [KMH] [Entered: 08/21/2020 09:37 AM] (1) |
| Aug 20, 2020 | 10 | Docketing Statement for the Appellants Apotex Corp. and Apotex Inc.. Service: 08/20/2020 by email. [716253] [20-2134] [Sherry Rollo] [Entered: 08/20/2020 03:19 PM] (5) |
| Aug 20, 2020 | 9 | Certificate of Interest for Appellants Apotex Corp. and Apotex Inc.. Service: 08/20/2020 by email. [716251] [20-2134] [Sherry Rollo] [Entered: 08/20/2020 03:18 PM] (5) |
| Aug 20, 2020 | 8 | Entry of appearance for Steven Eric Feldman; Sherry L. Rollo; Daniel R. Cherry; John D. Cravero as counsel for Appellants Apotex Corp. and Apotex Inc.. Service: 08/20/2020 by email. [716250] [20-2134] This document is non-compliant. See Doc No.[11] [Sherry Rollo] [Entered: 08/20/2020 03:17 PM] (4) |
| Aug 20, 2020 | 7 | Docketing Statement for the Appellee Eagle Pharmaceuticals, Inc.. Service: 08/20/2020 by email. [716229] [20-2134] [Daniel Brown] [Entered: 08/20/2020 02:53 PM] (2) |
| Aug 20, 2020 | 6 | Certificate of Interest for Appellee Eagle Pharmaceuticals, Inc.. Service: 08/20/2020 by email. [716225] [20-2134] [Daniel Brown] [Entered: 08/20/2020 02:51 PM] (3) |
| Aug 20, 2020 | 5 | Entry of appearance for Daniel G. Brown; Marc N. Zubick; Kenneth G. Schuler; Gabriel K. Bell as counsel for Appellee Eagle Pharmaceuticals, Inc.. Service: 08/20/2020 by email. [716223] [20-2134] [Daniel Brown] [Entered: 08/20/2020 02:48 PM] (2) |
| Aug 20, 2020 | 4 | Docketing Statement for the Appellees Cephalon, Inc. and Teva Pharmaceuticals International GmbH. Service: 08/20/2020 by email. [716143] [20-2134] [Ben Picozzi] [Entered: 08/20/2020 12:39 PM] (2) |
| Aug 20, 2020 | 3 | Certificate of Interest for Appellees Cephalon, Inc. and Teva Pharmaceuticals International GmbH. Service: 08/20/2020 by email. [716142] [20-2134] [Ben Picozzi] [Entered: 08/20/2020 12:37 PM] (3) |
| Aug 20, 2020 | 2 | Entry of appearance for David I. Berl; Adam D. Harber; Shaun P. Mahaffy; Ben Picozzi; Matthew W. Lachman as counsel for Appellees Cephalon, Inc. and Teva Pharmaceuticals International GmbH. Service: 08/20/2020 by email. [716141] [20-2134] [Ben Picozzi] [Entered: 08/20/2020 12:35 PM] (2) |
| Aug 6, 2020 | 1 | Appeal docketed. Received: 08/04/2020. [713019]Entry of Appearance is due on 08/20/2020. Certificate of Interest is due on 08/20/2020. Docketing Statement is due on 08/20/2020. Appellant's brief is due on 10/05/2020. [KMH] [Entered: 08/06/2020 12:31 PM] (142) |
